Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study. - Chen IA; Chang RI; Yu CC; Lin TP; Yang CY (Therapeutic advances in urology, 2026)